This weekend, Congress completed work on a large spending bill that maintains funding for colorectal cancer research and prevention. In the current budget-cutting environment, holding the line on research and prevention programs is a remarkable accomplishment and reflects the power of grassroots advocacy.

I congratulate the Fight Colorectal Cancer volunteers who took action this year to protect colorectal cancer research and prevention funding. We should be proud of our achievements, but we cannot become complacent. We must prepare for the Fiscal Year 2013 budget battle that lies ahead. Please register to attend Fight Colorectal Cancer’s Call-on Congress next March – where advocates from around the country will be urging their legislators to continue to protect colorectal cancer research funding.

The following are the spending outcomes on Fight Colorectal Cancer’s three appropriations priorities:

• The Colorectal Cancer Control Program (CRCCP)
• The National Cancer Institute (NCI) and
• The Peer Reviewed Cancer Research Program (PRCRP)

Note: The funding levels described below for the CRCCP and NCI do not reflect a 0.189 percent across-the-board cut that will be applied to all discretionary programs under the Departments of Labor, Health and Human Services (HHS), Education, with the exception of the Pell Grant Program.

Colorectal Cancer Control Program
Despite threats of deep spending cuts, the Centers for Disease Control and Prevention (CDC) received a slight increase, which allowed funding for the CRCCP to be preserved at its current level of $43.07 million. The CRCCP currently funds colorectal cancer programs in 25 states and four tribal organizations. Funded sites can use up to one-third of funds to provide no-cost screening services to eligible low-income men and women age 50-64. The remaining two-thirds of funds are for colorectal cancer education and outreach strategies. Maintaining CRCCP funding allows education and screening programs currently underway to continue. If funding for CRCCP was increased, education and screening programs could be expanded to more states.

National Institutes of Health

For FY2012, the NIH will receive a $299 million increase in its budget, with the various Institutes and Centers receiving
proportional increases, resulting in $5.082 billion for the NCI. The outcome reflects compromise between the $1 billion increase for the NIH in the House Labor-HHS -Education spending bill and the $190 million cut in the Senate bill. In addition to $30.698 billion for the NIH, the bill also includes $10 million for the Cures Acceleration Network (CAN), which was established under the Patient Protection and Affordable Care Act. The purpose of CAN is to accelerate the testing of high-need cures – drugs, biologics and devices – that are not attractive for development within the commercial market.

Peer Reviewed Cancer Research Program
Another important victory for the colorectal cancer community was the inclusion of $12.8 million for the Department of Defense’s (DoD) PRCRP. Comparatively, the PRCRP received $16 million for FY2011. While the program’s budget was decreased, some in Congress have called for the elimination of non-defense spending, including funding for medical research, from the DoD spending bill. The PRCRP funds research on several forms of cancer, including colorectal cancer.

Earlier this month, the House Labor, Health and Human Services (HHS), and Education Appropriations Subcommittee announced that it has postponed consideration of its fiscal year (FY) 2012 spending bill until September.

Delayed consideration of this bill, which funds the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), gives colorectal cancer advocates more time to contact their House and Senate lawmakers when they return home in August.

The message: Funding for colorectal cancer research and prevention must be a priority.

In August, consider participating in town hall meetings with lawmakers. Or, take the time to find out if your lawmakers will be at a county fair or local parade and stop by to say hello and share your story and our message.

Many representatives and senators post their town hall meeting schedules on their websites (like Rep. Chris Gibson of upstate New York, pictured at left). You can find your Members’ of Congress websites at www.house.gov and www.senate.gov.

We need to help lawmakers understand that even in these times of fiscal austerity, there are significant human and economic consequences to cutting medical research and prevention funding.

Even President Obama in his recent address to the nation said that while the government must live within its means, there are still things that we need to pay for in this country, including medical research.

Some lawmakers may tell you that the government can’t afford to increase, or even sustain, current funding for medical research. Lawmakers must be reminded they have a choice when it comes to funding priorities. Advocates need to ask lawmakers to protect colorectal cancer research and prevention funding. If we do not, no one else will.

Recently, Fight Colorectal Cancer held a free patient webinar on how to make a difference in the fight for cancer research funding. A recording of the webinar is available on our website. Take a few minutes to learn what you can do to take effective action.

This afternoon, by a vote of 336-87, the House passed the Fiscal Year 2012 Department of Defense Appropriations bill (H.R. 2219). The bill includes funding for critical national security needs while also providing essential funding for health and quality of life programs for the men and women of the Armed Services and their families.

The final bill includes more than $223 million for cancer research, including $12.8 million for the Department of Defense’s Peer Reviewed Cancer Research Program (PRCRP) that funds colorectal cancer research.

The PRCRP is an opportunity to advance the best research to eradicate diseases and support the warfighter for the benefit of the American public. The research target diseases like colorectal cancer that directly impact the welfare of the American military, their families and the public. For example, a study published in the June 2009 edition of Cancer Epiemology Biomarkers & Prevention, researchers found that colorectal cancer was one of the most common forms of cancer among active-duty military personnel. Screening rates in the military for colorectal cancer, like in the general population, are much too low. In 2008, only about 58% of those in the military who should be screened for colorectal cancer had been screened.

The mission of the PRCRP is to foster ground-breaking research, team science, and partnerships for the development of better prevention, early detection, and more effective treatment of cancer. The funding supports high-quality medical research, concentrating its resources on research mechanisms which complement rather than duplicate the research approaches of the other major funders of medical research in the United States. The PRCRP strives to recognize and fund innovative research, which can ‘leap frog’ scientific advances towards achieving the goals of the programs. This focus can be high risk, yet can yield high gains. CDMRP funds research that may be considered too risky or preliminary for the NIH/NCI to support.

The research potentially helps to decrease the more than $1 billion that the Department of Defense (DoD) spends on cancer care each year.

“Fight Colorectal Cancer, on behalf of the thousands of war fighters at risk for or living with colorectal cancer, thanks the US House of Representatives for reaffirming its commitment to funding cancer research through the CDMRP. While we are grateful that cancer research will continue through this program, we remain determined to do more and do better for the men and women living with cancer while wearing a uniform.” — Carlea Bauman, President, Fight Colorectal Cancer

Although colorectal cancer research has only been funded through the PRCRP since Fiscal Year 2010, we are already seeing innovative research taking place. Dr. Carlos Alvarez at the Research Institute at Nationwide Children’s Hospital, Dr. C. Couto at Ohio State University, and Dr. Kun Huang at Ohio State University recently received funding for a research proposal identifying genetic pathways that are affected in cancer risk and disease progression by studying military working dogs.

Colorectal cancer is the second leading cause of cancer death in America. As Congress moves forward with completing its work on the Fiscal Year 2012 appropriations bills we hope it will continue to fund proven research programs that have the potential to reduce the billions of tax-payer dollars we spend on cancer care.

The next step is for the Senate to consider the bill. Please take a minute to contact your Senators about the importance of Fiscal Year 2012 funding for colorectal cancer programs.

Walter Pincus’s latest article published by the Washington Post criticizes the health research funding in the defense appropriations bill as both earmarked funding and unneeded duplicative funding. He is wrong.

It Isn’t Earmarked Funding

The defense health programs don’t come close to meeting the Administration’s own definition of an earmark.

The Office of Management and Budget (OMB) defines earmarks as “funds provided by the Congress for projects or programs where the congressional direction (in bill or report language) circumvents the merit-based or competitive allocation process, or specifies the location or recipient, or otherwise curtails the ability of the Administration to control critical aspects of the funds allocation process.”

The fact that President Obama does not request funding for important health research programs does not make them “earmarks” if Congress chooses to fund them.

All funding through the Congressionally Directed Medical Research Programs (CDMRP) is competitively awarded. Research proposals go through a two-tier review process of scientific peer review, followed by a programmatic review that includes basic researchers, clinicians, consumers, and military members.

To qualify, CDMRP research must have relevance to service members and their families. The research potentially helps to decrease the more than $1 billion that the Department of Defense (DoD) spends on cancer care each year.

The Research Isn’t Duplicative

Back in 2007, COL Harris, testified before the House Defense Appropriations Subcommittee about the Congressionally Directed Medical Research Programs. In answering how the CDMRP research is different than that of research funded by the National Institutes of Health (NIH) and the National Cancer Institute (NCI), COL Harris explained that “[t]wo hallmarks of CDMRP are innovation and inclusion of survivors in decision-making processes. CDMRP strives to recognize and fund innovative research, which can ‘leap frog’ scientific advances towards achieving the goals of the programs. This focus can be high risk, yet can yield high gains. CDMRP funds research that may be considered too risky or preliminary for the NIH/NCI to support.”

The CDMRP supports high-quality medical research, concentrating its resources on research mechanisms which complement rather than duplicate the research approaches of the major funders of medical research in the United States. Although the diseases included in this program are diverse, the research on these disease types is often synergistic. For example, investigators increasingly look at the molecular profiles of cancer, often finding connections across cancers affecting different body sites. Advances or progress related to one cancer fuels the research on the other cancers in this program, and treatments initially approved for one cancer are routinely found to be effective in others. For example, treatments approved initially for kidney cancer have proven effective in other solid tumors outside the scope of this program. Monoclonal antibodies, designed to target specific molecules on the surface of cancer cells, were first used in the treatment of non-Hodgkin lymphoma. They are now the most widely used form of cancer immunotherapy, with clinical trials in progress for almost every type of cancer.

It’s A Good Investment

Advocacy groups and members of Congress have been strong champions of Pentagon-conducted research because Defense Department researchers get results with minimal tax-payer investment.

Funding for the CDMRP is an opportunity to advance the best research to eradicate diseases and support the warfighter for the benefit of the American public. These research programs target diseases that impact directly the welfare of the American military, their families and the public. The CDMRP supports medical research on several forms of cancer (breast, blood, colorectal, melanoma, pediatric, brain, lung, ovarian, and prostate) and other diseases (like neurofibromatosis, bone marrow failure, and tuberous sclerosis complex) that have led to breakthroughs on nerve regeneration and traumatic brain injury. The CDMRP also funds research on Gulf War Illness, psychological health, spinal cord injury, and hearing and vision loss (which comprise a significant portion of current battlefield injuries). Other activities target diseases and conditions such as Lupus, Multiple Sclerosis, Scleroderma, ALS, and Autism, conditions that can have a devastating effect on the families those in service leave behind.

Funding Successful and Innovative Research

Cancer research performed by the Pentagon is unique in that it funds high-risk, high-reward projects that may yield nothing or a spectacular breakthrough. Many of these projects have gathered enough data to receive funding from the National Cancer Institute, taking the research even further. The Pentagon’s annual budget for ovarian cancer research is only $12 million, but it has yielded multiple discoveries that benefit women with the disease. One example is the OVA1TM test, which helps physicians determine whether a pelvic mass is benign or malignant. Another breakthrough is a compound that slows ovarian cancer growth.

The DoD Prostate Cancer Research Program, through its sponsorship of Phase I/II trials through the Prostate Cancer Clinical Trials Consortium, has helped to bring to market 3 new medicines for men with advanced prostate cancer that were approved by the FDA in 2010-11: namely, PROVENGE® (sipuleucel-T) – Dendreon Corporation, XGEVA™ (denosumab) – Amgen Inc, and ZYTIGA™ (abiraterone acetate) – Johnson & Johnson were all made possible through DoD support of a comprehensive clinical trials network of 13 US centers of excellence for prostate cancer research. Also, more than 2,700 patients have had access to 83 clinical trials since 2005 through the DoD’s Prostate Cancer Clinical Trials Consortium.

Research funded by the Tuberous Sclerosis Complex Research Program (TSCRP) has led to the development of animal models of tuberous sclerosis complex (TSC) and clinical trials, resulting in the first drug specifically to treat TSC being approved by the FDA in 2010.  These same animal models are shedding light on the consequences and potential treatment for traumatic brain injury.

The ALS Research Program has led to the identification and development of new chemical compounds which are now being developed for potential treatments for ALS, a fatal disease for which there currently is no effective treatment. The program also has enabled the parallel development of many new approaches to therapies for ALS, increasing the chances of finding a meaningful treatment for all people with the disease, including our heroes serving in the military who are twice as likely to die from ALS as the general public.

Dr. Carlos Alvarez at the Research Institute at Nationwide Children’s Hospital, Dr. C. Couto at Ohio State University, and Dr. Kun Huang at Ohio State University recently received funding for an innovative research proposal identifying genetic pathways that are affected in cancer risk and disease progression by studying military working dogs.

Colorectal cancer is the second leading cause of cancer death in America. As Congress moves forward with the fiscal year 2012 appropriations bills I hope it will continue to fund proven research programs that have the potential to reduce the billions of tax-payer dollars we spend on cancer care.

– Nancy Roach was a member of the FY10 PRCRP Integration Panel responsible for the programmatic review of grant applications submitted to the program for funding through the Department of Defense.  Ms. Roach is a founder of both Fight Colorectal Cancer (formerly the C3: Colorectal Cancer Coalition) and the Colon Cancer Alliance. She currently serves as the Chair of the Board of Directors for Fight Colorectal Cancer. Ms. Roach also serves on the Executive Committee of the FDA-Duke Clinical Trial Transformation Initiative. In her role as a patient advocate, Ms. Roach also serves on a number of advisory boards for the National Cancer Institute.

This week the House Appropriations Committee approved $223 million for cancer research, including $12.8 million for the Department of Defense’s Peer Reviewed Cancer Research Program (PRCRP) that funds colorectal cancer research. Next week, the full House will consider the bill.

During consideration of the bill by the full House, there may be amendments offered to eliminate or reduce this important funding. Keep reading for more information on why the PRCRP funding is important and what you can do to help ensure the funding stays in the fiscal year 2012 defense appropriations bill.

The PRCRP is an opportunity to advance the best research to eradicate diseases and support the warfighter for the benefit of the American public. These research target diseases like colorectal cancer that directly impact the welfare of the American military, their families and the public. For example, a study published in the June 2009 edition of Cancer Epiemology Biomarkers & Prevention, researchers found that colorectal cancer was one of the most common forms of cancer among active-duty military personnel. Screening rates in the military for colorectal cancer, like in the general population, are much too low. In 2008, only about 58% of those in the military who should be screened for colorectal cancer had been screened.

The mission of the PRCRP is to foster ground-breaking research, team science, and partnerships for the development of better prevention, early detection, and more effective treatment of cancer. The funding supports high-quality medical research, concentrating its resources on research mechanisms which complement rather than duplicate the research approaches of the other major funders of medical research in the United States.

The PRCRP is very important. Dr Carlos Alvarez at the Research Institute at Nationwide Children’s Hospital, Dr C Couto at Ohio State University, and Dr Kun Huang at Ohio State University recently received a PRCRP funding grant for the following innovative research proposal:

“Despite great progress in genetics, little is known about the majority of genetic and environmental causes of complex diseases. One limitation is the great genetic complexity of the human population, in which many variations of many genes can be associated with disease. Another limitation is that it has not yet been possible to study groups of individuals over time, collecting standardized clinical, environmental, and molecular or genetic data. In humans, this has not been possible largely due to cost and ethics. Here we propose that dogs are the ideal mammal in which to identify genetic and environmental contributions to disease. Military Working Dogs (MWD) offer an unparalleled advantage in understanding the genetic mechanisms that contribute to the development of naturally occurring complex diseases. Genetic complexity in dog breeds is very dramatically reduced compared to humans, and each breed is predisposed to a different limited group of disorders. Nearly 400 inherited diseases, including diverse cancers, are well characterized in dogs. Almost all are similar to human disorders and, where known, involve the same biochemical pathways. Other major strengths of dog models is that they share an environment with humans, the also receive a high level of health care, but age five times as fast. Studies on pets share the limitations of bias that occur in the human population. MWD however have extensive clinical, behavioral, and environmental records. By using these records in combination with molecular and genetic characterizations we hope to identify environmental effects that alter heritable traits. Specifically we will integrate different kinds of information and conduct statistical analysis to identify exactly which gene variations and environmental effects are associated with increased cancer incidence or worse outcomes. We propose this would be the most powerful study of its kind to date. The successful completion of this work will yield information about genetic and environmental contributions to cancer. This information will not only be relevant to human cancers, but is likely to reveal completely novel understanding of geneenvironment interactions. The ultimate applicability of this work will be the identification of genetic pathways that are affected in cancer risk and disease progression. Importantly, the development of new treatments based on our findings will be vastly accelerated in clinical studies of pet dogs with cancer. For example, if drugs targeting the biochemical pathways implicated are already in human use or in development, those could be used in dogs without requirements for clinical studies that typically take six or more years in humans. Thus our proposal has the potential to quickly identify novel genetic and environmental contributions to cancer, and to result in the rapid development of new treatments.”

Research proposals submitted for funding through the PRCRP program go through a two-tier review process.  The first level is a scientific peer review conducted by an external panel recruited specifically for each peer review session.  The second-tier review is a programmatic review conducted by an “Integration Panel.”  Members of the Integration Panel include basic researchers, clinicians, consumers, and military members.  Research proposals that receive a recommendation from the Integration Panel are awarded funding in the form of 1-5 year grants, contracts, or cooperative agreements.

The Peer Reviewed Cancer Research Program is just one of several innovative research programs within the Congressionally Directed Medical Research Programs (CDMRP). We are very concerned that amendments may be offered during floor consideration of the fiscal year 2012 appropriations bill to reduce or eliminate this important research funding. We will be working hard to prevent this from happening, but we also need your help to ensure the funding stays in the bill….

Please take a minute to call your Representative and ask them to vote no on any amendments that would reduce or eliminate funding for the Peer Reviewed Cancer Research Program.

Dial 202-224-3121, and ask the operator to connect you to your Representative. When you are connected to the office, you can use the following talking points:

Introduce yourself: Give the staffer your name and address (they need to know you are in their district)

Tell them why you are an expert: Explain your personal connection to colorectal cancer (are you a survivor, family member of a patient, caregiver, physician, nurse, etc)

Explain what you want: “I urge you to vote NO on any amendments that would reduce funding for the Congressionally Directed Medical Research Programs. The $12.8 million in fiscal year 2012 defense appropriations bill (H.R. 2219) for the Peer Reviewed Cancer Research Program is life-saving research funding needed to continue a highly successful peer-reviewed, competitive grant program.”

By a vote of 217-203 the House approved the fiscal year 2012 agriculture appropriations bill (H.R. 2112). The bill includes funding for the FDA.

Total funding for the FDA, including user fees, is $3.7 billion. This is about 0.09% above last year’s funding level which reflects an increase in mandatory programs over $3 billion. This means that the overall total for the fiscal year 2012 agriculture bill is higher than last year’s bill even though the bill cuts millions from the FDA’s budget.

The bill cuts discretionary funding for the FDA by $284 million. This reduction in discretionary funding for the FDA is an 11.5% cut from last year’s funding level. The reduction includes an $87 million cut from the FDA’s food safety budget.

The $284 million in cuts to the FDA’s budget:
• May delay or prevent development and implementation of a regulatory pathway for bio-similars;
• Significantly reduce efforts to stop importation of illegal products;
• Slow efforts to approve generic drugs;
• Undercut our nation’s investment in development of medical countermeasures in the case of pandemic disease or bio-terrorism.

In addition to the $284 million cut in FDA funding, the House also produced a committee report on the bill. Here are a few highlights from the report:
• In order to focus resources, FDA is strongly encouraged to set up a pilot project to expedite imports for highly compliant importers
• In order to achieve independent post-market surveillance, FDA is directed to submit plans to Congress for an independent office to carry out this work.

We have hopes for a higher allocation in the Senate, and will keep you updated as the Senate Appropriations Committee moves forward with their bill.

On Wednesday March 9, advocates from all across the country are heading to the hill to talk to Congress as part of Fight Colorectal Cancer’s annual Call-on Congress lobby day. You can join them in the fight from your home or office. We’ve put together everything you need to be a virtual lobbyist.

The Virtual Lobby Day is an opportunity for patients, survivors, caregivers, health care providers, and researchers across the country to join together with one voice to tell Congress that you believe that the time has come for Congress to make colorectal cancer a top legislative priority!

Between your phone calls and the in-person visits from advocates who are in DC, Congress will hear us loud and clear. Join us today, and raise your voice.

When you call your legislators, you will be asking them to support the following 5 legislative priorities:

• The Colorectal Cancer Prevention, Early Detection, and Treatment Act (H.R. 912; S. 494).
• The Fight Colorectal Cancer Stamp Act (H.R. 893).
• Funding for the Peer Reviewed Cancer Research Program at the Department of Defense for Fiscal Year 2011 and 2012.
• Funding for the Centers for Disease Control and Prevention’s Colorectal Cancer Control Program (CRCCP) for Fiscal Year 2011 and 2012.
• Funding for the National Cancer Institute for Fiscal Year 2011 and 2012.

Before you call, please review the following documents (click each to download PDF file):

• Colorectal Cancer Basic Facts
• Background on the Colorectal Cancer Prevention, Early Detection, and Treatment Act (H.R. 912/S. 494)
• Background on the Fight Colorectal Cancer Act (H.R. 893)
• Background on the need for continued funding for colorectal cancer research and cancer control programs (use this to backup/support the requests for appropriations funding)

Each of the documents has talking points on each bill and request. You don’t need to use all of the talking points just pick out one or two that you are most comfortable with to tell the offices when you call them.

You should plan out what you want to say before you call so that you can get the “ask” across in a few brief sentences.

Below is a step-by-step guide of what to say when you reach your legislators.

1. The first thing to do when you call is identify yourself as a constituent. Give the office your name and address. You want to make sure your legislators know you live in their state and district!
2. Then go through the “ask.”You should say, “I’m calling today to ask my Senator/Representative to:
   • COSPONSOR the Colorectal Cancer Prevention, Early Detection, and Treatment Act (H.R. 912; S. 494).
   • COSPONSOR the Fight Colorectal Cancer Stamp Act (H.R. 893).
   • SUPPORT funding for the Peer Reviewed Cancer Research Program (PRCRP) at the Department of Defense for Fiscal Year 2011 and 2012. At a minimum I request that you fund the CRCCP at its current level of $16 million for the remainder of FY2011. And for Fiscal Year 2012, please fund this program at $75 million.
   • SUPPORT funding for the Centers for Disease Control and Prevention’s (CDC) Colorectal Cancer Control Program (CRCCP) for Fiscal Year 2011 and 2012. At a minimum I request that you fund the CRCCP at its current level of $45 million for the remainder of FY2011. And for Fiscal Year 2012, please fund this program at $70 million.
   • SUPPORT funding for the National Cancer Institute (NCI) for Fiscal Year 2011 and 2012. At a minimum I request that you fund the NCI at its current level of $5.1 billion for the remainder of FY2011. And for Fiscal Year 2012, please fund this program at $5.76 billion.”
3. At the end of the call, remember to thank the staffer you talk with for their time and for “passing my request on to your boss.”

Please call all three of your legislators (your two Senators and your Representative) with this request. Simply dial the Capitol switchboard at 202-224-3121 and ask the operator to transfer you to your legislators.

The time you take to prepare and call-in as a virtual lobbyist will make a big difference. We need your voice to help us get members signed onto these bills as cosponsors.

If you have any questions about exactly what to say during your phone calls, please call Fight Colorectal Cancer’s policy director Catherine Knowles at 202-276-5682 or email her at Catherine@FightColorectalCancer.org.

This evening, the House of Representatives paid tribute to outgoing House Appropriations Chairman David Obey. The spontaneous tribute from his fellow appropriators was made during debate on the last appropriations bill Chairman Obey will oversee.

The bill passed the Senate earlier in the day, and House passage by a vote of 193-165 sends the measure to the President for his review and signature.

The short-term continuing resolution funds the federal government through March 4, 2011. It funds most programs including the Department of Defense cancer research programs, the National Institutes of Health cancer research programs, and the cancer control programs at the Centers for Disease Control and Prevention at fiscal year 2010 levels.

When the new Congress convenes, they will need to deal with funding the remainder of fiscal year 2011 (from March 5 until September 30), and we expect that the new Congress will reduce funding levels. House and Senate Republican leaders say they want to implement a cut of about 22 percent to bring non-security discretionary spending back to fiscal year 2008 levels. What Congressional leaders haven’t said is which programs should be cut, and by how much.

In today’s budget climate, it will be difficult to secure any funding increases for cancer research – even for investments with the proven long-term impact of biomedical research.

The only way we will get the members of the 112th Congress to make the fight against cancer a top legislative priority and continue to fund innovative and life-saving colorecal cancer research programs is if we tell them why it should be a priority. Come climb the steps of the Capitol with us – http://link.fightcrc.org/TakeAction. Taking the time to bring your cancer story to the halls of Congress will make a difference!

The House and Senate are finishing up a continuing resolution (CR) that will fund the federal government through December 3, and plan to adjourn after voting on the CR until November. Under the CR, funding will continue at FY 2010 enacted levels for most programs – including cancer research programs at the National Institutes of Health and colorectal cancer control programs at the Centers for Disease Control and Prevention. Congress is not expected to finish the fiscal year 2011 appropriations bills until after the election.

Take action today, and tell Congress to increase fiscal year 2011 cancer research funding. As they head home for the election, take a minute to remind Members that they have work to finish when they come back to DC in November. Tell your Senators and Representative that you expect them to make colorectal cancer a top priority.

On Facebook? Take action and share this alert with your friends and family so that they can help in the fight too.

The Colorectal Cancer Coalition is working with Congressional leaders to increase fiscal year 2011 funding for the following colorectal cancer research and control programs:

• $50 million in funding for the Peer Reviewed Cancer Research Program (PRCRP) at the Department of Defense
• $35.2 billion for the National Institutes of Health (NIH)
• $5.79 billion for National Cancer Institute (NCI)
• $240 million for the National Center on Minority Health and Health Disparities (NCMHD)
• $601 million for Centers for Disease Control and Prevention (CDC) cancer programs
• $50 million for CDC’s National Comprehensive Cancer Control Program
• $50 million for CDC’s Colorectal Cancer Screening, Education & Outreach Initiative
• $65 million for CDC’s National Program of Cancer Registries
• $2.857 billion for the Food and Drug Administration (FDA)

Thanks to research, we have made great strides in the fight against colorectal cancer and treatment options have expanded to seven drugs. Today, people diagnosed with metastatic colorectal cancer are living longer than ever. But there is more work to be done, and we need continued federal funding of research programs to win the fight against colorectal cancer.

Take action today, and help us secure an increase in federal funding for fiscal year 2011.

Today, the House Appropriations Agriculture Subcommittee met to consider the fiscal year 2011 bill that funds the Food and Drug Administration (FDA).  The Subcommittee approved $2.571 billion in funding for the FDA.

This is an increase of $214 million above last year’s level and $55 million above the President’s request.  C3 is very pleased with this proposed increase, and applauds the leadership of Chairwoman De Lauro, Ranking Member Kingston and the members of the Subcommittee.

Earlier this month, C3 advocates went to Capitol Hill to urge Congress to increase funding for the FDA.  Register today as a C3 advocate, and we will update you on what you can do to help us make sure this increased funding for the FDA stays in the bill as it moves through the appropriations process.

Chairwoman DeLauro released the following statement following subcommittee approval of the bill highlighting the importance of FDA funding while also emphasizing some areas of Congressional concern with the agency:

“The Food and Drug Administration is always one of the most important agencies under our purview, particularly given that more than 20 cents of every dollar spent by American consumers is on an FDA-regulated product…I believe there is strong leadership at the FDA under Commissioner Hamburg.  But I remain concerned about the existing structure at the agency, especially as it pertains to drug safety.

So we have included targeted resources to help make a difference in this area, including an additional $65 million for staff to review generic drug applications, drug company ads targeted at consumers, and, for the first time to my knowledge, an increase specifically for review of drug company ads to doctors.  We are also funding more safety reviews for drugs already on the market, more inspections of foreign drug facilities, and providing more funds to safeguard clinical trials and improve the oversight of imported foods. For example, the bill includes:

• A $15 million increase over the request for the office of generic drugs
• A $3 million increase for the review of direct consumer ads
• A $2 million for the review of communications to medical professionals in the Division of Drug Marketing and Communication
• A $7 million increase over the request for the Center for Devices and Radiological Health
• A $16 million increase over the request for the center and field activities in the Center for Food Safety and Applied nutrition related to imported food safety.

In addition, we have included report language that we worked on with Sen. Grassley and Congressman Hinchey that outlines the need to create an independent office on post-market drug evaluation.  Thank you Congressman Hinchey for your leadership on this issue.  As we learned from the hearing the subcommittee held about the Avandia case, there may be an inherent bias when those that approve drugs continue to play a role in determining their safety in a post-market environment.

We have also included report language that we worked on with Congresswoman Emerson that directs FDA to provide a report on the status of developing standards for a track and trace system for prescription drugs, one that would document all parties involved in the prior sale, purchase, and trade of a given prescription drug beginning with the manufacturer.  This is critical to improving the security of the drug supply chain from counterfeit or other substandard products and to protecting consumers.  Thank you Congresswoman Emerson for your work and leadership on this.”

Congresswoman DeLauro’s complete statement discussing all the funding in the bill is available on the House Appropriations Committee website.